Directed evolution of adeno-associated virus yields enhanced gene delivery vectors
The DOI matches its Crossref record; 51 of the 53 references it cites were found in a registry or an index.
Abstract
Adeno-associated viral vectors are highly safe and efficient gene delivery vehicles. However, numerous challenges in vector design remain, including neutralizing antibody responses, tissue transport and infection of resistant cell types. Changes must be made to the viral capsid to overcome these problems; however, very often insufficient information is available for rational design of improvements. We therefore applied a directed evolution approach involving the generation of large mutant capsid libraries and selection of adeno-associated virus (AAV) 2 variants with enhanced properties. High-throughput selection processes were designed to isolate mutants within the library with altered affinities for heparin or the ability to evade antibody neutralization and deliver genes more efficiently than wild-type capsid in the presence of anti-AAV serum. This approach, which can be extended to additional gene delivery challenges and serotypes, directs viral evolution to generate 'designer' gene delivery vectors with specified, enhanced properties.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, directed evolution has been applied to generate AAV variants capable of evading neutralizing antibodies in vitro and in vivo.68–72”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [68]
In the citing paper
“New AAV variants created through directed evolution withstood up to 35-fold higher in vitro concentrations of pooled human antibodies than AAV2.”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [68]
In the citing paper
“These antibody neutralization properties also led to enhanced transduction in vivo, where AAV variants were capable of significantly higher transduction in the liver, heart and muscle than AAV2 in mice passively immunized with human antibodies.”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [68]
In the citing paper
“Compared with natural variants, the engineered AAV-DJ variant, consisting of residues from AAV2, AAV8, and AAV9 variants, has been shown to transduce hepatocytes in the presence of human intravenous IgG [194, 195].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [194]
In the citing paper
“The best-performing variants selected from this screen were reported to evade antibodies and enhance the gene expression [88].”
From Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy (2022) · cites this paper as [88]
Citations
Cites
Rapid evolution of a protein in vitro by DNA shuffling
Stemmer, W. P. C. (1994) · Nature · doi:10.1038/370389a0 · Cited by 1,932
Yeast surface display for screening combinatorial polypeptide libraries
Boder, E. T., & Wittrup, K. D. (1997) · Nature Biotechnology · doi:10.1038/nbt0697-553 · Cited by 1,760
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Summerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406
Zolotukhin, S., Byrne, B. J., Mason, E., Zolotukhin, I., Potter, M., Chesnut, K., Summerford, C., Samulski, R. J., & Muzyczka, N. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300938 · Cited by 1,312
Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070
Kay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022
Xiao, X., Li, J., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.8098-8108.1996 · Cited by 912
Sonic hedgehog regulates adult neural progenitor proliferation in vitro and in vivo
Lai, K., Kaspar, B. K., Gage, F. H., & Schaffer, D. V. (2003) · Nature Neuroscience · doi:10.1038/nn983 · Cited by 799
Self-citationRabinowitz, J. E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., & Samulski, R. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.2.791-801.2002 · Cited by 762
Cited by
Items 301–400 of 535
Seek and destroy: targeted adeno-associated viruses for gene delivery to hepatocellular carcinoma
Dhungel, B. P., Jayachandran, A., Layton, C. J., & Steel, J. C. (2017) · Drug Delivery · doi:10.1080/10717544.2016.1247926 · Cited by 24
“These vectors were subsequently incubated with pre-immunized rabbit sera and found to have an enhanced resistance to preexisting NAbs compared to the wild-type vector in vivo (Maheshri et al., 2006).”
BackgroundLotfinia, M., Abdollahpour‐Alitappeh, M., Hatami, B., Zali, M. R., & Karimipoor, M. (2019) · Clinical and Experimental Medicine · doi:10.1007/s10238-019-00557-8 · Cited by 28
Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O. J., & Kleinschmidt, J. A. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.139 · Cited by 30
“…ligands at an exposed position of the AAV capsid that is naturally involved in receptor binding, thereby enabling the generation of AAV mutant capsid libraries (Mu¨ller et al. , 2003; Perabo et al. , 2003; Maheshri et al. , 2006; Grimm et al. , 2008; Koerber et al. , 2008; Li et al. , 2008).”
Expert opinion in biological therapy: update on developments in lung gene transfer
Griesenbach, U., & Alton, E. W. F. W. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.735656 · Cited by 27
“In addition, molecular evolution studies based on DNA shuffling and related recombination techniques are currently being utilized to generate new “artificial” AAV vectors, which show promise for lung gene transfer [16-18].”
MethodEfficient gene delivery to photoreceptors using AAV2/rh10 and rescue of the Rho−/− mouse
Palfi, A., Chadderton, N., O’Reilly, M., Nagel‐Wolfrum, K., Wolfrum, U., Bennett, J., Humphries, P., Kenna, P. F., Millington‐Ward, S., & Farrar, J. (2015) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2015.16 · Cited by 24
Therapeutic application of the CRISPR system: current issues and new prospects
Lee, M., & Kim, S. (2019) · Human Genetics · doi:10.1007/s00439-019-02028-2 · Cited by 25
Generation of Targeted Adeno-Associated Virus (AAV) Vectors for Human Gene Therapy
Liu, Y., Siriwon, N., Rohrs, J. A., & Wang, P. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150531171653 · Cited by 26
“In the last few years, much research has been devoted to apply this strategy to various in vitro and in vivo systems [38, 102-104].”
BackgroundMethodInfluentialComprehensive Review of Osteogenesis Imperfecta: Current Treatments and Future Innovations
Chaugule, S. R., Constantinou, C. K., John, A. A., Micha, D., Eekhoff, E. M. W., Gravallese, E. M., Gao, G., & Shim, J. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.191 · Cited by 30
“167 Pseu-dotyping (packaging AAV genomes in different viral cap-sids) and capsid engineering (creating hybrid capsids) have been used to enhance transduction ef fi ciency and target speci fi city.”
Zhou, W., Yang, J., Zhang, Y., Hu, X., & Wang, W. (2022) · MedComm · doi:10.1002/mco2.155 · Cited by 31
Goertsen, D., Goeden, N., Flytzanis, N. C., & Gradinaru, V. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.07.010 · Cited by 26
Lalejini, A., Dolson, E. L., Vostinar, A. E., & Zaman, L. (2022) · eLife · doi:10.7554/elife.79665 · Cited by 26
“…; Chen and Arnold, 1993 ; Esvelt et al., 2011 ), genetic circuits ( Yokobayashi et al., 2002 ), microorganisms ( Ratcliff et al., 2012 ), viruses ( Burrowes et al., 2019 ; Maheshri et al., 2006 ), and whole microbial communities ( Goodnight, 1990 ; Swenson et al., 2000 ; Sánchez et al., 2021 ).”
BackgroundLiu, Q., Huang, W., Zhao, C., Zhang, L., Meng, S., Gao, D., & Wang, Y. (2013) · Journal of Medical Virology · doi:10.1002/jmv.23647 · Cited by 24
“This approach directed viral evolution to generate “designer” gene delivery vectors with specified, enhanced properties and yielded several neutralizing antibodyevading phenotypes [Maheshri et al., 2006].”
BackgroundJang, J.-H., Koerber, J. T., Gujraty, K. V., Bethi, S. R., Kane, R. S., & Schaffer, D. V. (2010) · Gene Therapy · doi:10.1038/gt.2010.81 · Cited by 22
Self-citationSun, S., & Schaffer, D. V. (2018) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2017.12.011 · Cited by 24
Self-citationCalton, M. A., Croze, R. H., Burns, C., Beliakoff, G., Vazin, T., Szymanski, P., Schmitt, C., Klein, A., Leong, M., Quezada, M., et al. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.14.1 · Cited by 21
“29,30,32,34 Cap genes were sequenced by third-party DNA sequencing facilities and analyzed using Geneious software (Biomatters, Aukland, New Zealand).”
Self-citationAAV-based CRISPR-Cas9 genome editing: Challenges and engineering opportunities
Kabadi, A. M., Mejía‐Guerra, M. K., Graef, J. D., Khan, S. Z., Walton, E. M., Wang, X., Gersbach, C. A., & Potter, R. A. (2023) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2023.100517 · Cited by 29
Creation of a cardiotropic adeno-associated virus: the story of viral directed evolution
Yang, L., & Xiao, X. (2013) · Virology Journal · doi:10.1186/1743-422x-10-50 · Cited by 24
“The original attempts to modify the AAV cap gene respectively involved random peptide insertion [39], random mutagenesis [40], and DNA shuffling [41].”
BackgroundBuscara, L., Gross, D., & Danièle, N. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040258 · Cited by 22
Chemical approaches to probe and engineer AAV vectors
Pham, Q. T., Glicksman, J., & Chatterjee, A. (2024) · Nanoscale · doi:10.1039/d4nr01300j · Cited by 26
Virus nanotechnology for intratumoural immunotherapy
Omole, A. O., Zhao, Z., Chang-Liao, S., de Oliveira, J. F. A., Boone, C. E., Sutorus, L., Sack, M., Varner, J. A., Fiering, S., & Steinmetz, N. F. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00231-z · Cited by 21
“Viruses and VLPs are biological nanoscale materials that offer a design space for versatile applications, including drug and gene delivery 47,48 , light harvesting 49,50 , data and energy storage 51,52 and nanobiocatalysis 53,54 .”
Selot, R., Arumugam, S., Mary, B., Cheemadan, S., & Jayandharan, G. R. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00441 · Cited by 20
“Error prone PCR and DNA shuffling methods have been employed to identify Nab escape AAV (Maheshri et al., 2006; Perabo et al., 2006).”
MethodEngineering novel adeno-associated viruses (AAVs) for improved delivery in the nervous system
Carneiro, A. D., & Schaffer, D. V. (2024) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2024.102532 · Cited by 22
Self-citationTargeted nanoscale therapeutics for myocardial infarction
Sullivan, H. L., Gianneschi, N. C., & Christman, K. L. (2020) · Biomaterials Science · doi:10.1039/d0bm01677b · Cited by 20
The intersection of vector biology, gene therapy, and hemophilia
Lisowski, L., Staber, J. M. R., Wright, J. F., & Valentino, L. A. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12586 · Cited by 19
Immunogenicity of Novel AAV Capsids for Retinal Gene Therapy
Gehrke, M., Diedrichs‐Möhring, M., Bogedein, J., Büning, H., Michalakis, S., & Wildner, G. (2022) · Cells · doi:10.3390/cells11121881 · Cited by 20
“Residues highlighted in magenta represent known epitopes for human and rabbit neutralizing antibodies [31,32,35].”
BackgroundAllogenic microglia replacement: A novel therapeutic strategy for neurological disorders
Rao, Y., & Peng, B. (2023) · Fundamental Research · doi:10.1016/j.fmre.2023.02.025 · Cited by 20
“An obstacle to expanding their application is due to the immune response to the viral-based gene delivery system and products of foreign transgenes [125–127] .”
BackgroundViral vector-mediated gene transfer for CNS disease
Snyder, B. R., Boulis, N. M., & Federici, T. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903514074 · Cited by 27
“Most recently, the generation of mosaic or chimeric AAV vectors through AAV display [46] or DNA shuffling [47] has yielded targeted vectors with selective/enhanced features.”
BackgroundResearch advances in gene therapy approaches for the treatment of amyotrophic lateral sclerosis
Nizzardo, M., Simone, C., Falcone, M., Riboldi, G. M., Rizzo, F., Magri, F., Bresolin, N., Comi, G. P., & Corti, S. P. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0881-5 · Cited by 22
“Most recently, the generation of mosaic or chimeric AAV vectors through AAV display [64] or DNA shuffling [65]”
BackgroundLi, Y., Li, J., Liu, Y., Shi, Z., Liu, H., Wei, Y., & Yang, L. (2019) · Gene Therapy · doi:10.1038/s41434-019-0081-8 · Cited by 21
Kotterman, M., Beliakoff, G., Croze, R., Vazin, T., Schmitt, C., Szymanski, P., Leong, M., Quezada, M., Holt, J., Barglow, K., et al. (2021) · doi:10.1101/2021.06.24.449775 · Cited by 20
Self-citationEvasion of Pre-Existing Immunity to Cas9: A Prerequisite for Successful Genome Editing In Vivo?
Wignakumar, T., & Fairchild, P. J. (2019) · Current Transplantation Reports · doi:10.1007/s40472-019-00237-2 · Cited by 19
Palaschak, B., Marsic, D., Herzog, R. W., Zolotukhin, S., & Markusic, D. M. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.04.004 · Cited by 19
ApoE gene therapy to treat hyperlipidemia and atherosclerosis.
Harris, J., Evans, & Owen, J. S. (2006) · PubMed · Cited by 27
Serguera, C., & Bemelmans, A. (2014) · Revue Neurologique · doi:10.1016/j.neurol.2014.09.004 · Cited by 22
Adachi, K., & Nakai, H. (2010) · Gene Therapy and Regulation · doi:10.1142/s1568558610000197 · Cited by 20
“It has also been employed to create stealth rAAV variants that evade host immune responses (Grimm et al., 2008; Maersch et al., 2010; Maheshri et al., 2006; Perabo et al., 2006a).”
Materiomically Designed Polymeric Vehicles for Nucleic Acids: Quo Vadis?
Kumar, R. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.2c00346 · Cited by 19
Xie, Q., Spilman, M. S., Meyer, N., Lerch, T. F., Stagg, S. M., & Chapman, M. S. (2013) · Journal of Structural Biology · doi:10.1016/j.jsb.2013.09.004 · Cited by 17
“AAV-DJ is among the first of a growing number of AAV gene delivery vehicles showing varying tissue tropisms in pre-clinical studies and produced through the application of combinatorial technologies (Asokan et al., 2012; Maheshri et al., 2006).”
BackgroundEffects of Thermally Induced Configuration Changes on rAAV Genome’s Enzymatic Accessibility
Xu, Y., Guo, P., Zhang, J., Chrzanowski, M., Chew, H., Firrman, J., Sang, N., Diao, Y., & Xiao, W. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.06.005 · Cited by 19
Viren als Bauelemente für Materialien und Strukturen
Fischlechner, M., & Donath, E. (2007) · Angewandte Chemie · doi:10.1002/ange.200603445 · Cited by 17
Ghaedi, M., Lotfi, A. S., & Soleimani, M. (2010) · Tissue and Cell · doi:10.1016/j.tice.2010.03.007 · Cited by 16
Oncolytic adenovirus-mediated therapy for prostate cancer
Halldén, G., & Sweeney, K. G. (2016) · Oncolytic Virotherapy · doi:10.2147/ov.s63047 · Cited by 17
“125,129 Ablation of the Ad5 binding to erythrocytes and hepatocyte uptake are also desirable traits that could be selected for using this strategy to enable systemic delivery.”
Sun, J., Hua, B., Chen, X., Samulski, R. J., & Li, C. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.016 · Cited by 16
Kunze, M., Huber, A., KRAJEWSKI, A. C., Lowden, E., Schuhmann, N., Buening, H., Hallek, M. J., Noack, M. J., & Perabò, L. (2009) · Journal of Dentistry · doi:10.1016/j.jdent.2009.03.001 · Cited by 19
Sites in the AAV5 capsid tolerant to deletions and tandem duplications
Hida, K., Won, S. Y., Pasquale, G. D., Hanes, J. S., Chiorini, J. A., & Ostermeier, M. (2010) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.01.009 · Cited by 16
Wang, S., & Xiao, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052213 · Cited by 20
“Methods for generating diverse libraries consist of error-prone PCR and a staggered extension process [97], a DNA shuffling-based approach [98,99], the random peptide insertion into surface regions [100,101], etc.”
Fakhiri, J., Landegger, L. D., & Grimm, D. (2020) · Hearing Research · doi:10.1016/j.heares.2020.108092 · Cited by 15
Zhong, C., Jiang, W., Wang, Y., Sun, J., Wu, X., Zhuang, Y., & Xiao, X. (2022) · Human Gene Therapy · doi:10.1089/hum.2021.129 · Cited by 17
“33 However, their application is limited by NAbs.”
Maurer, A. C., Diaz, A. K. C., & Vandenberghe, L. H. (2019) · Journal of Virology · doi:10.1128/jvi.02013-18 · Cited by 17
Leonard, J. N., Ferstl, P., Delgado, A. R., & Schaffer, D. V. (2007) · Biotechnology and Bioengineering · doi:10.1002/bit.21355 · Cited by 16
“A large fraction of the human population harbors neutralizing antibodies against many AAV serotypes, and while AAV vectors have been engineered to evade pre-existing immunity (Maheshri et al., 2006), such vectors may also become less effective during subsequent treatments if the initial injection contains excess viral…”
BackgroundMethodInfluentialSelf-citationKang, S., Lu, K., Leelawattanachai, J., Hu, X., Park, S., Park, T., Min, I. M., & Jin, M. M. (2013) · Gene Therapy · doi:10.1038/gt.2013.29 · Cited by 14
Gene therapies for hemophilia hit the mark in clinical trials
Pickar, A., & Gersbach, C. A. (2018) · Nature Medicine · doi:10.1038/nm.4492 · Cited by 15
Gong, H., Yuan, N., Shen, Z., Tang, C., Shipp, S. D., Liling, Q., Lu, Y., Andolina, I. M., Zhang, S., Wu, J., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102685 · Cited by 14
Viral vectors for cystic fibrosis gene therapy: What does the future hold?
Griesenbach, U., Inoue, Hasegawa, & Alton, E. W. F. W. (2010) · Virus Adaptation and Treatment · doi:10.2147/vaat.s8887 · Cited by 14
“Molecular evolution studies based on DNA shuffling and related recombination techniques are currently being utilized to generate new AAV vectors.(45) Excoffon et al identified a recombinant AAV virus that transduced organotypic human lung cultures 100-fold better than parental strains, although the performance of this…”
Primate models of schizophrenia: future possibilities
Simen, A. A., Dileone, R., & Arnsten, A. F. T. (2009) · Progress in brain research · doi:10.1016/s0079-6123(09)17913-x · Cited by 15
Introduction to Viral Vectors and Other Delivery Methods for Gene Therapy of the Nervous System
Manfredsson, F. P. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3271-9_1 · Cited by 17
Novel Lung Tropic Adeno-Associated Virus Capsids for Therapeutic Gene Delivery
Carneiro, A. D., Lee, H., Lin, L. W., van Haasteren, J., & Schaffer, D. V. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.169 · Cited by 13
“89 In addition, techniques such as DNA shuffling 145,146 and chemical modification of the AAV capsid 147,148 have been applied to escape NAB binding.”
Self-citationNickase fidelity drives EvolvR-mediated diversification in mammalian cells
Hurtado, J. E., Schieferecke, A. J., Halperin, S. O., Guan, J., Aidlen, D., Schaffer, D. V., & Dueber, J. E. (2025) · Nature Communications · doi:10.1038/s41467-025-58414-0 · Cited by 13
“…; speci fi c and high-af fi nity binding of proteins to ligands 5,6 , proteins 7 , or nucleic acids 8 for research and therapeutic applications; and improved infectivity, tissue-speci fi c tropism, or manufacturing of engineered viral vectors for the delivery of gene therapies to target cells 9 – 11 .”
Self-citationAltering Tropism of rAAV by Directed Evolution
Marsic, D., & Zolotukhin, S. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3271-9_11 · Cited by 12
Schieferecke, A. J., Lee, H., Chen, A. T., Kilaru, V., Williams, J. K., & Schaffer, D. V. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.12.015 · Cited by 15
Self-citationKoerber, J. T., & Schaffer, D. V. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-248-3_10 · Cited by 15
“For selection protocols involving infection of a cell line, such as HEK293 (19), care should be taken to avoid infection with a large (>1000) number of virions per cell [i.”
BackgroundMethodInfluentialSelf-citationXu, M., Li, J., Xie, J., He, R., Su, Q., Gao, G., & Tai, P. W. L. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.253 · Cited by 11
Overview of analytics needed to support a robust gene therapy manufacturing process
Ramsey, J. P., Khatwani, S. L., Lin, M. J., Boregowda, R., Surosky, R. T., & Ramelmeier, R. A. (2021) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2021.100339 · Cited by 12
Evading the AAV Immune Response in Mucopolysaccharidoses
Piechnik, M., Sawamoto, K., Ohnishi, H., Kawamoto, N., Ago, Y., & Tomatsu, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103433 · Cited by 12
“Modifying the AAV capsid, specifically at epitopal sites, to reduce the neutralizing antibody targeting is achieved through strategies such as directed evolution [69], capsid chemical modification [70,71], and structure-based engineering [72,73].”
MethodTumor Targeting Using Canine Parvovirus Nanoparticles
Singh, P. N. P. (2009) · Current topics in microbiology and immunology · doi:10.1007/978-3-540-69379-6_6 · Cited by 11
Asokan, A., & Samulski, R. J. (2006) · Nature Biotechnology · doi:10.1038/nbt0206-158 · Cited by 12
Developing New Vectors for Retinal Gene Therapy
Zin, E. A., Öztürk, B. E., Dalkara, D., & Byrne, L. C. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041291 · Cited by 14
A facile chemical strategy to synthesize precise AAV-protein conjugates for targeted gene delivery
Pham, Q. T., Glicksman, J., Han, B., Shahraeini, S. S., Jewel, D., Loynd, C., Roy, S. J. S., & Chatterjee, A. (2025) · Molecular Therapy Oncology · doi:10.1016/j.omton.2025.201040 · Cited by 12
Promise of adeno-associated virus as a gene therapy vector for cardiovascular diseases
Bera, A., & Sen, D. (2017) · Heart Failure Reviews · doi:10.1007/s10741-017-9622-7 · Cited by 13
La conception de vecteurs adaptés à la thérapie génique oculaire
Khabou, H., & Dalkara, D. (2015) · médecine/sciences · doi:10.1051/medsci/20153105015 · Cited by 17
“En vectorologie, elle permet de modifier les propriétés d’un vecteur pour obtenir un phénotype précis (d’où l’expression d’évolution dirigée), par exemple modifier la capside virale pour améliorer le tropisme du virus envers un tissu particulier ou encore obtenir des variants échappant au système immunitaire [33].”
McConnell, K. I., Slater, J. H., Han, A., West, J. L., & Suh, J. (2011) · Soft Matter · doi:10.1039/c0sm01209b · Cited by 11
Design and characterization of 4D-710, an aerosolized gene therapy for cystic fibrosis lung disease
Calton, M. A., Croze, R. H., Sullivan, T. H., Collins, S., Tucker, S., Whittlesey, K. J., Kim, D. H., Nye, J. A., Beliakoff, G., Quezada, M., et al. (2025) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2025-0243ma · Cited by 10
Self-citationZhong, C., Chen, Z., Xia, Y., Wu, J., Zhang, F., Cheng, C., Wu, X., Zhuang, Y., & Xiao, X. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.04.011 · Cited by 10
“Therapeutic genes delivered by AAV may be an effective form of treatment, since these can sustain stable and persistent expression in vivo.(46)”
BackgroundViral-mediated gene therapy in pediatric neurological disorders
Peng, J., Zou, W., Wang, X., Zhang, Z., Huo, R., & Yang, L. (2023) · World Journal of Pediatrics · doi:10.1007/s12519-022-00669-4 · Cited by 11
“…properties and desired variations, for example, selecting the ideal vector capsids through high-throughput screening in anti-AAV sera and isolating mutants with a high affinity for heparin or evasion of antibody neutralization, thus transducing genes more efficiently than wild-type capsids [76].”
Phages as Tools for Functional Nanomaterials Development
Chung, W., Sena, M., Merzlyak, A., & Lee, S. (2011) · Elsevier eBooks · doi:10.1016/b978-0-08-055294-1.00064-7 · Cited by 8
Chimeric AAV Cap sequences alter gene transduction
Ward, P., & Walsh, C. (2009) · Virology · doi:10.1016/j.virol.2009.01.012 · Cited by 11
Dai, H., Liu, Z., Jiang, W., & Kuhn, R. J. (2013) · Journal of Virology · doi:10.1128/jvi.01054-13 · Cited by 10
Adeno-associated viral serotypes differentially transduce inhibitory neurons within the rat amygdala
de Solis, C. A., Hosek, M. P., Holehonnur, R., Ho, A., Banerjee, A., Luong, J. A., Jones, L. E., Chaturvedi, D., & Ploski, J. E. (2017) · Brain Research · doi:10.1016/j.brainres.2017.07.023 · Cited by 11
“…1965; Bantel-Schaal and zur Hausen, 1984; Blacklow et al., 1968; Gao et al., 2004; Hoggan et al., 1966), and two created through directed evolution (AAV2/DJ; AAV2/DJ8)(Grimm et al., 2008; Koerber et al., 2008; Maheshri et al., 2006) for their ability to transduce neurons within the rat BLA and CeA.”
Translational Aspects of Adeno-Associated Virus–Mediated Cardiac Gene Therapy
Ziegler, T., Ishikawa, K., Hinkel, R., & Kupatt, C. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.229 · Cited by 9
“32,33 In order to evaluate these newly designed rAAVs and choose the most promising serotype, monitoring tissue distribution and transduction efficacy is of paramount importance.”
Engineered AAV vectors for improved central nervous system gene delivery
Kotterman, M. A., & Schaffer, D. V. (2015) · Neurogenesis · doi:10.1080/23262133.2015.1122700 · Cited by 10
Self-citationAil, D., & Dalkara, D. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-27681-1_18 · Cited by 9
Kwak, G., Lee, D., & Suk, J. S. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2282535 · Cited by 9
“In this study, four distinct mutants comprising T716A mutation were shown to provide threefold greater compared to wild-type AAV2 in the presence of serum [208].”
BackgroundMethodYuan, L., Ling, C., Shoti, J., Yang, H., Nath, A., Keeler, G. D., Qing, K., & Srivastava, A. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102196 · Cited by 11
Engineered AAV capsid transport mutants overcome transduction deficiencies in the aged CNS
Sandoval, I. M., Kelley, C. M., Bernal-Conde, L. D., Steece‐Collier, K., Marmion, D. J., Davidsson, M., Crosson, S. M., Boye, S. L., Boye, S. L., & Manfredsson, F. P. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102332 · Cited by 9
ACIDES: on-line monitoring of forward genetic screens for protein engineering
Nemoto, T., Ocari, T., Planul, A., Tekinsoy, M., Zin, E. A., Dalkara, D., & Ferrari, U. (2023) · Nature Communications · doi:10.1038/s41467-023-43967-9 · Cited by 7
Low immunogenic bio-nanocapsule based on hepatitis B virus escape mutants
Jung, J., Somiya, M., Jeong, S., Choi, E. K., & Kuroda, S. (2017) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.11.017 · Cited by 8
Bönnemann, C. G. (2021) · Cell · doi:10.1016/j.cell.2021.08.031 · Cited by 8
Gene Delivery into Cells and Tissues
Duvall, C. L., Prokop, A., Gersbach, C. A., & Davidson, J. M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-398358-9.00035-5 · Cited by 10
Augmented transgene expression in transformed cells using a parvoviral hybrid vector
Krüger, L., Eskerski, H., Dinsart, C., Cornelis, J. J., Rommelaere, J., Haberkorn, U., & Kleinschmidt, J. A. (2008) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701113 · Cited by 10
Huang, X., Wang, X., Li, L., Qizhao, W., Xu, W., Wu, W., Xie, X., & Diao, Y. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17858 · Cited by 6
Identification and validation of novel engineered AAV capsid variants targeting human glia
Giacomoni, J., Åkerblom, M., Habekost, M., Fiorenzano, A., Kajtez, J., Davidsson, M., Parmar, M., & Björklund, T. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1435212 · Cited by 7
“…onto permissive sites of the production plasmid (leading to random amino acids; Girod et al., 1999; Rabinowitz et al., 1999; Wu et al., 2000; Maheshri et al., 2006; Dalkara et al., 2013; Korbelin et al., 2016), or phage display (Nicklin et al., 2001; Chen et al., 2009) are used to generate…”
BackgroundCho, M., Jung, K., Kim, S., Kim, I., Kim, M., Shin, M., Lee, H., Park, K. I., & Jang, J. (2019) · Gene Therapy · doi:10.1038/s41434-019-0057-8 · Cited by 7
Gene Therapy for Cardiac Transplantation
Mendiola, M., Chiang, Y., Roan, J., & Bowles, D. E. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.102865 · Cited by 9
PEG-mediated transduction of rAAV as a platform for spatially confined and efficient gene delivery
Zou, L., Wang, J., Fang, Y., & Tian, H. (2022) · Biomaterials Research · doi:10.1186/s40824-022-00322-1 · Cited by 8
“7-kilobase single-stranded DNA genome [1, 2].”
BackgroundKim, Y., Kim, E., Oh, S., Yoon, Y.-E., & Jang, J. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.034 · Cited by 7
“14,15 Among the shortfalls of the AAV vectors, their rapid inactivation by neutralizing antibodies (NAbs) may be the most important barrier that considerably reduces the therapeutic efficacy of AAV-based gene therapy.”
Adeno-Associated Virus and AAV Vectors for Gene Delivery
Carter, B., Burstein, H., & PELUSO, R. W. (2008) · CRC Press eBooks · doi:10.1201/9780849387999.ch6 · Cited by 7
Song, Q., Wu, J., Zhang, Q., Wu, S. V., Luo, X., Xu, M., Xu, Y., Wang, G., Yu, H., Chen, H., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101522 · Cited by 8
Büning, H., Fehse, B., Ivics, Z., Kochanek, S., Koehl, U., Kupatt, C., Mussolino, C., Nettelbeck, D. M., Schambach, A., Uckert, W., et al. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.29178.hbu · Cited by 7
“…United States, were the first to report on successful production and selection of capsid variants with distinct features through error-prone PCR. 44,45 Dirk Grimm (Heidelberg, at that time in the team of Mark Kay, Stanford) developed in competition to Jude Samulski’s laboratory (United States) the…”
Identification of Novel Retinal Pericyte-Targeting rAAV Vectors Through Directed Evolution
Patel, D. D., Marsic, D., Periasamy, R., Zolotukhin, S., & Lipinski, D. M. (2022) · Translational Vision Science & Technology · doi:10.1167/tvst.11.8.28 · Cited by 6
Combination of Peglated-H1/HGFK1 Nanoparticles and TAE in the Treatment of Hepatocellular Carcinoma
Gao, D., Xu, X., Liu, L., Liu, L., Zhang, X., Liang, X., Cen, L., Liu, Q., Yuan, X., & Yu, Z. (2022) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-022-04153-7 · Cited by 6
McConnell, K. I., Gomez, E. J., & Suh, J. (2012) · Acta Biomaterialia · doi:10.1016/j.actbio.2012.06.038 · Cited by 6
Metadata
- Authors
- Maheshri, N., Koerber, J. T., Kaspar, B. K., & Schaffer, D. V.
- Affiliations
- University of California, Berkeley (US)
- Abigail Wexner Research Institute (US)
- Corresponding author
- Schaffer, David V
- Venue
- Nature Biotechnology
- Published
- 2006-01-22
- Volume
- 24
- Issue
- 2
- Pages
- 198-204
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2102111681
- Cited by
- 538
- References
- 53
- Citations by year
- 2026: 20 · 2025: 20 · 2024: 29 · 2023: 31 · 2022: 31 · 2021: 25 · 2020: 31 · 2019: 33 · 2018: 19 · 2017: 26 · 2016: 23 · 2015: 33 · 2014: 32 · 2013: 31 · 2012: 23
- FWCI
- 15.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Science Foundation
- ALS Association
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- adeno-associated virus, AAV2, directed evolution, viral capsid, gene delivery vectors, heparin binding, antibody neutralization, high-throughput selection
- MeSH terms
- Adenoviridae, Genetic Vectors, Transfection, Genetic Therapy, Drug Delivery Systems, Gene Targeting, Directed Molecular Evolution, Genetic Enhancement
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.